← Leaderboards
Rong Stephanie Huang
University Of Chicago
$4,360,763
Attributed
$6,019,968
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2009–24$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,019,968 · 4
By mechanism
R01$5,144,661 · 2
K08$497,787 · 1
R21$377,520 · 1
Top collaborators
- Barbara E Stranger8 shared
- M Eileen Dolan2 shared
Most similar at University Of Chicago
Same institution · by research overlap
- Marcus Kronforst$4,381,920
- M Eileen Dolan$15,055,139
- Olufunmilayo I Olopade$31,360,913
- Alexander V Chervonsky$24,284,071
- Barbara E Stranger$7,251,389
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesSamplingPharmacogenomicsResponseDrug SensitivityCancer TherapyPharmaceutical PreparationsGene ExpressionAffectTumorGenetic VariantPredictive ModelingLymphoblastoid Cell LinePathway InteractionsGenome Wide Association StudyGeneticMalignant NeoplasmsIn VitroCancer Cell LineMortalityBaseCaringGenome-WideCancer Genomics
Grant awards (20)
Genetic mechanisms underlying sexual dimorphism in cancer and response to therapy$418,795
R01 · FY2024 · CA
Genetic mechanisms underlying sexual dimorphism in cancer and response to therapy$137,615
R01 · FY2024 · CA
Genetic mechanisms underlying sexual dimorphism in cancer and response to therapy$573,981
R01 · FY2023 · CA
Genetic mechanisms underlying sexual dimorphism in cancer and response to therapy$573,981
R01 · FY2022 · CA
Drug repurposing in breast cancer$435,224
R01 · FY2022 · CA · contact PI
Drug repurposing in breast cancer$446,914
R01 · FY2021 · CA · contact PI
Genetic mechanisms underlying sexual dimorphism in cancer and response to therapy$1
R01 · FY2021 · CA
Genetic mechanisms underlying sexual dimorphism in cancer and response to therapy$582,549
R01 · FY2020 · CA
Drug repurposing in breast cancer$437,700
R01 · FY2020 · CA · contact PI
Genetic mechanisms underlying sexual dimorphism in cancer and response to therapy$622,374
R01 · FY2019 · CA
Drug repurposing in breast cancer$428,276
R01 · FY2019 · CA · contact PI
Genetic mechanisms underlying sexual dimorphism in cancer and response to therapy$31,595
R01 · FY2019 · CA
Drug repurposing in breast cancer$455,656
R01 · FY2018 · CA · contact PI
Genome-wide interrogation of genetic signatures for glucocorticoid sensitivity$98,506
K08 · FY2014 · GM · contact PI
Genome-wide interrogation of genetic signatures for glucocorticoid sensitivity$100,666
K08 · FY2013 · GM · contact PI
Genome-wide interrogation of genetic signatures for glucocorticoid sensitivity$100,666
K08 · FY2012 · GM · contact PI
Genome-wide interrogation of genetic signatures for glucocorticoid sensitivity$100,666
K08 · FY2011 · GM · contact PI
Incorporation of microRNA expression in pharmacogenetic prediction models$171,600
R21 · FY2010 · CA
Genome-wide interrogation of genetic signatures for glucocorticoid sensitivity$97,283
K08 · FY2010 · GM · contact PI
Incorporation of microRNA expression in pharmacogenetic prediction models$205,920
R21 · FY2009 · CA